Anebulo Pharmaceuticals Statistics
Share Statistics
Anebulo Pharmaceuticals has 41.08M
shares outstanding. The number of shares has increased by 58.43%
in one year.
| Shares Outstanding | 41.08M |
| Shares Change (YoY) | 58.43% |
| Shares Change (QoQ) | 58.43% |
| Owned by Institutions (%) | 87.03% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 903 |
| FTD / Avg. Volume | 3.34% |
Short Selling Information
The latest short interest is 33.59K, so 0.08% of the outstanding
shares have been sold short.
| Short Interest | 33.59K |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.18% |
| Short Ratio (days to cover) | 4.68 |
Valuation Ratios
The PE ratio is -8.44 and the forward
PE ratio is -1.44.
Anebulo Pharmaceuticals's PEG ratio is
0.26.
| PE Ratio | -8.44 |
| Forward PE | -1.44 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 18.15 |
| P/FCF Ratio | -8.55 |
| PEG Ratio | 0.26 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Anebulo Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.46,
with a Debt / Equity ratio of 0.
| Current Ratio | 13.46 |
| Quick Ratio | 13.46 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -54.94 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-4,100,851.5 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -57.46% in the
last 52 weeks. The beta is -1.13, so Anebulo Pharmaceuticals's
price volatility has been lower than the market average.
| Beta | -1.13 |
| 52-Week Price Change | -57.46% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 1.59 |
| Relative Strength Index (RSI) | 37.01 |
| Average Volume (20 Days) | 27,027 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.31M |
| Net Income | -8.2M |
| EBITDA | -8.05M |
| EBIT | -8.05M |
| Earnings Per Share (EPS) | -0.32 |
Full Income StatementBalance Sheet
The company has 3.09M in cash and 0 in
debt, giving a net cash position of 3.09M.
| Cash & Cash Equivalents | 3.09M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -65.4M |
| Total Assets | 15.84M |
| Working Capital | 14.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -8.09M
and capital expenditures 0, giving a free cash flow of -8.09M.
| Operating Cash Flow | -8.09M |
| Capital Expenditures | n/a |
| Free Cash Flow | -8.09M |
| FCF Per Share | -0.31 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
